# Phase I Trial of a Recombinant COVID-19 Vaccine (CHO Cell)

> **NCT04636333** · PHASE1 · UNKNOWN · sponsor: **Jiangsu Province Centers for Disease Control and Prevention** · enrollment: 216 (estimated)

## Conditions studied

- COVID-19

## Interventions

- **BIOLOGICAL:** Two doses of middle-dose recombinant SARS-CoV-2 vaccine (CHO Cell) at the schedule of day 0, 14
- **BIOLOGICAL:** Three doses of middle-dose recombinant SARS-CoV-2 vaccine (CHO Cell) at the schedule of day 0, 14, 28
- **BIOLOGICAL:** Two doses of high-dose recombinant SARS-CoV-2 vaccine (CHO Cell) at the schedule of day 0, 14
- **BIOLOGICAL:** Three doses of high-dose recombinant SARS-CoV-2 vaccine (CHO Cell) at the schedule of day 0, 14, 28
- **BIOLOGICAL:** Two doses of placebo at the schedule of day 0, 14 #middle-dose group#
- **BIOLOGICAL:** Three doses of placebo at the schedule of day 0, 14, 28 #middle-dose group#
- **BIOLOGICAL:** Two doses of placebo at the schedule of day 0, 14 #High-dose group#
- **BIOLOGICAL:** Three doses of placebo at the schedule of day 0, 14, 28 #High-dose group#

## Key facts

- **NCT ID:** NCT04636333
- **Lead sponsor:** Jiangsu Province Centers for Disease Control and Prevention
- **Sponsor class:** NETWORK
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2020-10-30
- **Primary completion:** 2021-12-07
- **Final completion:** 2022-07-07
- **Target enrollment:** 216 (ESTIMATED)
- **Last updated:** 2022-03-31

## Collaborators

- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04636333

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04636333, "Phase I Trial of a Recombinant COVID-19 Vaccine (CHO Cell)". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT04636333. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*